Nice to see Jeffereys raise their target to $11 but with Oppenheimer at $8 and Barclays at $9, I think we'll be in for more upgrades once the difference between the independent review and the investigational sites is better explained. Irregardless, the trial clearly met it's primary endpoint and even though the placebo arm progressed after only 3 1/2 months, rida was still able to achieve a hazard ratio of .69-.72 which, imo, may bode well for the OS data.
btw, ASCO abstracts are usually available in May which should make the 2Q interesting.
